Don't Hold the Biologic or JAK with COVID-19 Vaccination A randomized clinical trial in inflammatory arthritis arthritis shows that temporarily holding biologic or Janus kinase (JAK) inhibitor therapy at the time of COVID-19 vaccination is not warranted. https://t.co/O9iJHEfp42

Uncontrolled report from UK Medical Cannabis Registry - 192 pts Rx w/ Cannabis for inflamm arthritis pain > 24 mos, showed improvement in BPI Severity, Pain VAS, SF-MPQ-2, SQS, EQ-5D-5L(P < .010) and in GAD-7 scores up (P < .001). https://t.co/fFwLl54XMi https://t.co/PJfQads4Au

Not all Low Dz Activity RA pts do the same. COREVITAS study of 6,856 RA pts w/ baseline CDAI 0-10. Comparing very low LDA (2.8-6: ~19.6%) vs high LDA >6-10 (31%);latter were twice as likely to have CDAI moderate Dz activity at 1 and 2 years https://t.co/mmc1wzJXWY https://t.co/5CotYBn0Zb

In early RA, initial b/tsDMARDs are better than MTX. Metanalysis of 29 RCTs (13387 pts), Vs MTX alone, initial b/tsDMARDs + MTX signif incr DAS28 remission 2 6 mos (RR 1.62) & 12 mos (RR 1.54). Benefits greater w/ higher baseline Dz, seropositivity https://t.co/exwVOc08xR https://t.co/Zcl62rxxJk

Retrospective cohort study of 387 ANCA-assoc. vasculitis pts Rx w/ GC +/- avacopan (AVA 52 vs 335 not Rx AVA). AVA use assoc w/ signif less severe infx (adj HR 0.22), & less pred use - but no diff in relapse risk was observed. https://t.co/GTtAf7KiqB https://t.co/WOOhAlnvFz

EBR Journal Club: Brepocitinib in Dermatomyositis (VALOR) The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits https://t.co/UoCQM4GtwL

Study of 64 Stills related #MAS pts (55 sJIA; 9 AOSD). All Rx GCs; 75% anakinra, 52% ciclosporin. Complete remission in 7, partial Rem in 64%; GCs tapered in 78% in median 40d. MAS recurred in 31%; 11% died; 1-year survival probability 93.75% https://t.co/HxhhpRsSMO https://t.co/WtJeFx0SGR

T-cell engager blinatumomab (CD3xCD19 TCE) was used for Deep B-cell depletion in 15 resistant RA pts (MDR-RA). @wk 12 9/15 CDAI LDA, 3/15 CDAI remission. Synovial B cells were depleted (4 of 5 biopsies) but not in lymph nodes. Later, 14/15 flared. No ICANs, 3/15 w/ CRS (gr 1) https://t.co/xLGZjkMmit

Metanalysis of IVIG in scleroderma (11 studies, 363 pts) showed IVIG to be safe; signif improvement in skin by mRSS (SMD −0.59; p 0.0019) & GI Dz (SMD −0.73; p 0.0012; I2 = 0%). W/ inflam myopathy signif reduction in CK (SMD −0.53; p<0.001) https://t.co/h53FrACCgA https://t.co/Y60ZfmnJgC

Danish national study (2003-2024) of 51,401 #PMR pts (24K PCPs, 27K secondary MDs): PMR incidence = 112/100K. PMR decr 53% in primary care & incr 30% in secondary care (overall 12% decline). Among PMR, GCA rate was 5.4/1,000 PYs, w/ median 68 days from PMR Dx. 28% & 22% were https://t.co/s168riRRLB

Italian retrospective study of 36 difficult #GCA pts (89% relapsed; 72% prev TCZ) showed Clinical remission 85%, 81%, & 83% at 3, 6, & 12 mos. GC-free remission increased to 15%, 28%, & 40% at 3, 6, & 12 mos. GCs d/c in 43%. Results at odds w/ ph III GCAptAIN RCT where SEC https://t.co/VnMSCPwMrn

Don't Hold the Biologic or JAK with COVID-19 Vaccination A randomized clinical trial in inflammatory arthritis arthritis shows that temporarily holding biologic or Janus kinase (JAK) inhibitor therapy at the time of COVID-19 vaccination is not warranted. https://t.co/moQIE09lvi

Steroids are easy to start and hard to stop. Hold the MTX, but not the biologic or JAK. And what’s the latest on avacopan? This week, Dr. Jack Cush reviews the rheumatology news you don’t want to miss: from new approvals and promising trial results to sobering Sjögren’s data, https://t.co/UC4RdHMaFS

Predicting and Preventing Psoriatic Arthritis Psoriatic arthritis is often underdiagnosed in those with psoriasis (PsO), leading to diagnostic delays an undertreatment. While certain factors in PsO portend a future PsA risk, a predictive profile and early intervention algorithm https://t.co/yvJr293MHs

Funny! Dr. Glaucomflecken explains the REPLENISH trial -secukinumab for the treatment of polymyalgia rheumatica https://t.co/7JDoMDJzeD https://t.co/ZBMcheSeCv